Recently there has been concern that febuxostat may be associated with increased cardiovascular risk than allopurinol,1 leading to a black-box warning by the Federal Drug Administration. Consistent with these concerns, Singh and Cleveland2 have recently reported that febuxostat also increased the risk for atrial fibrillation (AF) in a population-based cohort study of individuals greater than 65 years old, using Medicare data. The study evaluated individuals initiating allopurinol or febuxostat therapy and compared the incidence of AF with the prior year before starting treatment, controlling for comorbidities using the Charlson-Romero index and propensity matched Cox regression analysis.
Kuwabara M, B.C. (2020). Febuxostat and atrial fibrillation. EUROPEAN HEART JOURNAL, 41(30), 2916-2917 [10.1093/eurheartj/ehaa179].
Febuxostat and atrial fibrillation
Borghi CSecondo
Writing – Review & Editing
;
2020
Abstract
Recently there has been concern that febuxostat may be associated with increased cardiovascular risk than allopurinol,1 leading to a black-box warning by the Federal Drug Administration. Consistent with these concerns, Singh and Cleveland2 have recently reported that febuxostat also increased the risk for atrial fibrillation (AF) in a population-based cohort study of individuals greater than 65 years old, using Medicare data. The study evaluated individuals initiating allopurinol or febuxostat therapy and compared the incidence of AF with the prior year before starting treatment, controlling for comorbidities using the Charlson-Romero index and propensity matched Cox regression analysis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
